Terns Pharmaceuticals Stock Gains 5% Over Acquisition Deal With Merck

Merck agreed to acquire Terns Pharmaceuticals for $53.00 per share in cash; TERN shares rose about 5% on the announcement. The deal is an all-cash takeover by a Merck subsidiary (article truncates before reporting the full equity value). This strategic M&A is positive for Terns shareholders and is likely to reinforce M&A interest in the biotech sector.

Analysis

Merck agreed to acquire Terns Pharmaceuticals for $53.00 per share in cash; TERN shares rose about 5% on the announcement. The deal is an all-cash takeover by a Merck subsidiary (article truncates before reporting the full equity value). This strategic M&A is positive for Terns shareholders and is likely to reinforce M&A interest in the biotech sector.